Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need
To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant mor...
Saved in:
| Published in: | Journal of stroke Vol. 19; no. 1; pp. 50 - 60 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Korea (South)
Korean Stroke Society
01.01.2017
대한뇌졸중학회 |
| Subjects: | |
| ISSN: | 2287-6391, 1229-4101, 2287-6405 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment. We reviewed the pharmacological agents which reduced the risk of HT associated with delayed (beyond 4.5 hours post-stroke) tPA treatment in preclinical studies, which we classified into those that putatively preserve the blood-brain barrier (e.g., minocycline, cilostazol, fasudil, candesartan, and bryostatin) and/or enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte colony-stimulating factor). Recently, other new therapeutic modalities (e.g., oxygen transporters) have been reported which improved delayed tPA-associated outcomes by acting through other mechanisms. While the above-mentioned interventions unequivocally reduced delayed tPA-induced HT in stroke models, the long-term efficacy of these drugs are not yet established. Further optimization is required to expedite their future clinical application. The findings from this review indicate the need to explore the most ideal adjunctive interventions that will not only reduce delayed tPA-induced HT, but also preserve neurovascular functions. While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy. |
|---|---|
| AbstractList | To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment. We reviewed the pharmacological agents which reduced the risk of HT associated with delayed (beyond 4.5 hours post-stroke) tPA treatment in preclinical studies, which we classified into those that putatively preserve the blood-brain barrier (e.g., minocycline, cilostazol, fasudil, candesartan, and bryostatin) and/or enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte colony-stimulating factor). Recently, other new therapeutic modalities (e.g., oxygen transporters) have been reported which improved delayed tPA-associated outcomes by acting through other mechanisms. While the above-mentioned interventions unequivocally reduced delayed tPA-induced HT in stroke models, the long-term efficacy of these drugs are not yet established. Further optimization is required to expedite their future clinical application. The findings from this review indicate the need to explore the most ideal adjunctive interventions that will not only reduce delayed tPA-induced HT, but also preserve neurovascular functions. While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy.To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment. We reviewed the pharmacological agents which reduced the risk of HT associated with delayed (beyond 4.5 hours post-stroke) tPA treatment in preclinical studies, which we classified into those that putatively preserve the blood-brain barrier (e.g., minocycline, cilostazol, fasudil, candesartan, and bryostatin) and/or enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte colony-stimulating factor). Recently, other new therapeutic modalities (e.g., oxygen transporters) have been reported which improved delayed tPA-associated outcomes by acting through other mechanisms. While the above-mentioned interventions unequivocally reduced delayed tPA-induced HT in stroke models, the long-term efficacy of these drugs are not yet established. Further optimization is required to expedite their future clinical application. The findings from this review indicate the need to explore the most ideal adjunctive interventions that will not only reduce delayed tPA-induced HT, but also preserve neurovascular functions. While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy. To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment. We reviewed the pharmacological agents which reduced the risk of HT associated with delayed (beyond 4.5 hours post-stroke) tPA treatment in preclinical studies, which we classified into those that putatively preserve the blood-brain barrier (e.g., minocycline, cilostazol, fasudil, candesartan, and bryostatin) and/or enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte colony-stimulating factor). Recently, other new therapeutic modalities (e.g., oxygen transporters) have been reported which improved delayed tPA-associated outcomes by acting through other mechanisms. While the above-mentioned interventions unequivocally reduced delayed tPA-induced HT in stroke models, the long-term efficacy of these drugs are not yet established. Further optimization is required to expedite their future clinical application. The findings from this review indicate the need to explore the most ideal adjunctive interventions that will not only reduce delayed tPA–induced HT, but also preserve neurovascular functions. While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy. To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment. We reviewed the pharmacological agents which reduced the risk of HT associated with delayed (beyond 4.5 hours post-stroke) tPA treatment in preclinical studies, which we classified into those that putatively preserve the blood-brain barrier (e.g., minocycline, cilostazol, fasudil, candesartan, and bryostatin) and/or enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte colony-stimulating factor). Recently, other new therapeutic modalities (e.g., oxygen transporters) have been reported which improved delayed tPA-associated outcomes by acting through other mechanisms. While the above-mentioned interventions unequivocally reduced delayed tPA-induced HT in stroke models, the long-term efficacy of these drugs are not yet established. Further optimization is required to expedite their future clinical application. The findings from this review indicate the need to explore the most ideal adjunctive interventions that will not only reduce delayed tPA–induced HT, but also preserve neurovascular functions. While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy. KCI Citation Count: 0 |
| Author | Peña, Ike dela Davis, Willie Borlongan, Cesar Shen, Guofang |
| Author_xml | – sequence: 1 givenname: Ike dela surname: Peña fullname: Peña, Ike dela – sequence: 2 givenname: Cesar surname: Borlongan fullname: Borlongan, Cesar – sequence: 3 givenname: Guofang surname: Shen fullname: Shen, Guofang – sequence: 4 givenname: Willie surname: Davis fullname: Davis, Willie |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28178410$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002194038$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1UktvEzEQXqEi-qBXjshHOCT4uevlgBRFLUSqQIJUHC3bmU2c7Nqt7QD99zhJgygSvozl-R5j-zuvTnzwUFWvCB4LKdi7dUhjikk9xkQQ8aw6o1Q2o5pjcXLcs5acVpcprXFZUhAp6YvqlErSSE7wWWW_5agzLB0klAO6-pXBL9B8FcNgQv-QnUVzNwD67vwi_ERdiGiW7AqG0ijUsAE0j6DzAD6_RxOPbv0AGU17553VPfoMsHhZPe90n-DysV5Ut9dX8-mn0c2Xj7Pp5GZkeUPEiDRaWtEQ3BliuMbAiNaGWMkYAYM54NZI22nZQCsYp4Z2tsNNDYLUNSOWXVRvD7o-dmpjnQra7esyqE1Uk6_zmSKMYoplwc4O2EXQa3UX3aDjw56wPwhxqXQst-9BdcK0WramFZKVQaXhDa1rYaWVnEreFK0PB627rRlgYctTRN0_EX3a8W5VZvqhBMNNy9oi8OZRIIb7LaSsBpcs9L32ELZJEVnXdUualhfo67-9_pgcf7QA-AFgY0gpQqesyzq7sLN2vSJY7bKjSnbULjtqn51CG_9DOyr_h_AbZ8DExQ |
| CitedBy_id | crossref_primary_10_3390_ijms18122756 crossref_primary_10_3389_fphar_2020_615166 crossref_primary_10_3390_ijms241713289 crossref_primary_10_3390_ijms23031403 crossref_primary_10_1002_jbio_202300473 crossref_primary_10_1073_pnas_1820799116 crossref_primary_10_3171_2021_4_FOCUS21139 crossref_primary_10_3389_fneur_2020_594954 crossref_primary_10_1007_s40265_024_02121_5 crossref_primary_10_1080_14712598_2019_1551872 crossref_primary_10_1007_s10517_024_06264_z crossref_primary_10_1039_C9FO00908F crossref_primary_10_1016_j_lfs_2020_117450 crossref_primary_10_3390_ijms19103252 crossref_primary_10_1016_j_taap_2018_08_023 crossref_primary_10_1161_STROKEAHA_124_048464 crossref_primary_10_3389_fneur_2020_588479 crossref_primary_10_3390_ijms21082845 crossref_primary_10_3389_fphar_2019_00631 crossref_primary_10_1016_j_intimp_2021_108073 crossref_primary_10_1371_journal_pone_0190867 crossref_primary_10_1007_s43657_024_00209_2 crossref_primary_10_1080_14737175_2017_1371013 crossref_primary_10_1097_WNF_0000000000000534 crossref_primary_10_1007_s12035_018_0910_6 crossref_primary_10_1016_j_brainresbull_2025_111219 crossref_primary_10_1016_j_freeradbiomed_2017_12_027 crossref_primary_10_1177_09636897251315121 crossref_primary_10_3390_ijms19051533 crossref_primary_10_1139_cjpp_2020_0164 crossref_primary_10_1007_s11101_024_09923_1 crossref_primary_10_1016_j_phymed_2024_155362 crossref_primary_10_1111_ene_14531 crossref_primary_10_1186_s12868_020_0553_1 crossref_primary_10_1186_s12964_024_01752_1 crossref_primary_10_1242_dmm_048785 crossref_primary_10_1007_s44164_022_00013_0 crossref_primary_10_1097_CM9_0000000000003133 crossref_primary_10_1016_j_phymed_2023_155071 crossref_primary_10_1155_2022_7006281 crossref_primary_10_3389_fcell_2020_00053 crossref_primary_10_1186_s12883_019_1359_6 crossref_primary_10_1111_bcp_15651 crossref_primary_10_3389_fneur_2021_593887 crossref_primary_10_1007_s43657_022_00089_4 crossref_primary_10_1016_j_lfs_2019_116889 crossref_primary_10_1155_2018_5945128 crossref_primary_10_1007_s12975_017_0528_4 crossref_primary_10_1016_j_isci_2024_110031 crossref_primary_10_1152_jn_00638_2020 crossref_primary_10_1515_revneuro_2017_0076 crossref_primary_10_3390_ijms22020954 crossref_primary_10_4103_NRR_NRR_D_24_00720 crossref_primary_10_1016_j_expneurol_2019_113007 crossref_primary_10_1177_0271678X241237427 crossref_primary_10_1186_s12951_025_03540_6 crossref_primary_10_31083_j_jin2204088 crossref_primary_10_1177_1742395320905650 crossref_primary_10_1002_adma_202311803 crossref_primary_10_1038_s41598_020_77699_3 crossref_primary_10_1002_ana_25644 crossref_primary_10_3390_biomedicines10081870 crossref_primary_10_1080_10715762_2018_1521519 crossref_primary_10_3390_ijms25179442 crossref_primary_10_1016_j_ejphar_2020_173685 crossref_primary_10_1182_blood_2021012787 crossref_primary_10_1007_s40263_020_00783_9 crossref_primary_10_1016_j_ejphar_2018_06_028 crossref_primary_10_1016_j_neuropharm_2020_108326 crossref_primary_10_1016_j_taap_2022_116055 crossref_primary_10_4236_health_2020_125035 crossref_primary_10_1097_FJC_0000000000000945 crossref_primary_10_1016_j_biomaterials_2024_122818 crossref_primary_10_1080_00207454_2023_2286916 crossref_primary_10_1136_emermed_2018_208257 crossref_primary_10_1016_j_jep_2020_113410 crossref_primary_10_1111_jnc_16055 crossref_primary_10_1371_journal_pcbi_1012684 crossref_primary_10_4103_bc_bc_11_19 crossref_primary_10_3389_fcell_2020_00433 crossref_primary_10_1002_adtp_201900038 crossref_primary_10_3390_ijms19061635 crossref_primary_10_1186_s13020_025_01079_0 |
| Cites_doi | 10.1186/1471-2202-7-56 10.1007/s12975-012-0209-2 10.1161/STROKEAHA.111.618850 10.1111/ejn.12551 10.1161/STROKEAHA.111.618215 10.1097/00004647-199609000-00023 10.2174/1381612043382710 10.1016/j.ejphar.2015.07.035 10.1038/jcbfm.2014.208 10.1016/j.neuroscience.2011.12.042 10.3171/jns.1992.76.4.0571 10.1016/j.atherosclerosissup.2005.09.003 10.1177/0148607106030002108 10.1056/NEJMoa1411587 10.1016/j.jvs.2010.10.117 10.1007/s12035-014-8952-x 10.2174/187152707783220901 10.1161/01.STR.32.1.240 10.1016/j.neulet.2015.06.050 10.1111/j.1538-7836.2010.03897.x 10.1016/j.nicl.2014.02.003 10.1111/j.1538-7836.2007.02628.x 10.1371/journal.pone.0015178 10.1161/STROKEAHA.108.514026 10.1038/jcbfm.2010.33 10.1186/2045-8118-11-18 10.1001/archneur.1995.00540310040014 10.1097/HJH.0b013e32834bbb30 10.1007/s12035-015-9243-x 10.1161/01.STR.30.10.2230 10.1177/1941874415576204 10.1111/bcpt.12413 10.1161/STROKEAHA.116.014672 10.1161/01.cir.0000441139.02102.80 10.1161/01.STR.0000064841.47697.22 10.1038/jcbfm.2009.279 10.1056/NEJMoa1109842 10.1016/j.neuroscience.2012.06.015 10.1161/STROKEAHA.116.012619 10.1007/s11910-002-0051-0 10.1038/leu.2011.167 10.1161/STROKEAHA.110.582601 10.1161/STROKEAHA.109.564872 10.1038/jcbfm.2013.163 10.1016/S1474-4422(16)30076-X 10.1016/j.nbd.2003.12.016 10.1155/2013/362961 10.1007/s11064-013-1185-y 10.2353/ajpath.2007.060693 10.2174/138161212802002779 10.1161/STROKEAHA.113.002411 10.1056/NEJMoa0804656 10.1006/exer.1998.0637 10.1097/00062752-199805000-00013 10.1038/jcbfm.2013.203 10.1007/s12975-015-0444-4 10.1523/JNEUROSCI.3485-08.2008 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 Korean Stroke Society 2017 |
| Copyright_xml | – notice: Copyright © 2017 Korean Stroke Society 2017 |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA ACYCR |
| DOI | 10.5853/jos.2016.01515 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2287-6405 |
| EndPage | 60 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_1320208 oai_doaj_org_article_f5b9a89b95834718b472665c8c842847 PMC5307939 28178410 10_5853_jos_2016_01515 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: American Heart Association grantid: 16POST27520023 – fundername: Loma Linda University School of Pharmacy grantid: LLUSP-360033 |
| GroupedDBID | 5-W 53G 8JR 8XY AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK EF. GROUPED_DOAJ HYE KQ8 M48 OK1 PGMZT RPM NPM 7X8 5PM ACYCR |
| ID | FETCH-LOGICAL-c4715-17a8c5710fb1b4a0e31aab1c8331eb04e09b8cfa87e95342b2fcf076e516631c3 |
| IEDL.DBID | DOA |
| ISSN | 2287-6391 1229-4101 |
| IngestDate | Tue Nov 21 21:43:11 EST 2023 Fri Oct 03 12:43:33 EDT 2025 Thu Aug 21 18:27:18 EDT 2025 Fri Jul 11 09:07:25 EDT 2025 Thu Jan 02 22:30:57 EST 2025 Sat Nov 29 01:42:37 EST 2025 Tue Nov 18 21:50:58 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Blood-brain barrier Tissue plasminogen activator Hemorrhage Vasculature |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4715-17a8c5710fb1b4a0e31aab1c8331eb04e09b8cfa87e95342b2fcf076e516631c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/f5b9a89b95834718b472665c8c842847 |
| PMID | 28178410 |
| PQID | 1866691794 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_1320208 doaj_primary_oai_doaj_org_article_f5b9a89b95834718b472665c8c842847 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5307939 proquest_miscellaneous_1866691794 pubmed_primary_28178410 crossref_citationtrail_10_5853_jos_2016_01515 crossref_primary_10_5853_jos_2016_01515 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-01-01 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – month: 01 year: 2017 text: 2017-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of stroke |
| PublicationTitleAlternate | J Stroke |
| PublicationYear | 2017 |
| Publisher | Korean Stroke Society 대한뇌졸중학회 |
| Publisher_xml | – name: Korean Stroke Society – name: 대한뇌졸중학회 |
| References | ref13 ref57 ref12 ref56 ref15 ref59 ref14 ref58 dela Peña (ref50) 2015 ref53 ref52 ref11 ref55 ref10 ref54 ref17 ref16 ref19 ref18 Korninger (ref45) 1981 ref51 ref46 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref3 ref6 ref5 ref40 ref35 ref34 ref37 ref36 ref31 ref30 ref33 ref32 ref2 ref1 ref39 ref38 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref60 (ref4) 1997 ref61 20068577 - J Cereb Blood Flow Metab. 2010 Jun;30(6):1137-46 12677087 - Stroke. 2003 Apr;34(4):1056-83 20705929 - Stroke. 2010 Oct;41(10):2283-7 18045160 - CNS Neurol Disord Drug Targets. 2007 Oct;6(5):321-5 24352519 - Circulation. 2014 Jan 21;129(3):e28-e292 1545249 - J Neurosurg. 1992 Apr;76(4):571-7 20456746 - J Thromb Haemost. 2010 Jul;8(7):1567-74 6795744 - Thromb Haemost. 1981 Aug 28;46(2):561-5 16517955 - JPEN J Parenter Enteral Nutr. 2006 Mar-Apr;30(2):108-14 26149229 - Neurosci Lett. 2015 Aug 18;602:73-8 18815396 - N Engl J Med. 2008 Sep 25;359(13):1317-29 24045404 - J Cereb Blood Flow Metab. 2014 Jan;34(1):72-80 24281743 - J Cereb Blood Flow Metab. 2014 Feb;34(2):185-99 26288674 - Neurohospitalist. 2015 Jul;5(3):161-72 20216551 - J Cereb Blood Flow Metab. 2010 May;30(5):900-3 21737808 - Stroke. 2011 Sep;42(9):2633-5 25517348 - N Engl J Med. 2015 Jan 1;372(1):11-20 23658596 - Transl Stroke Res. 2013 Jun;4(3):279-85 26739964 - Transl Stroke Res. 2016 Aug;7(4):284-93 25120903 - Fluids Barriers CNS. 2014 Aug 10;11:18 11136943 - Stroke. 2001 Jan;32(1):240-8 24936414 - Neuroimage Clin. 2014 Mar 30;4:635-40 19834012 - Stroke. 2009 Dec;40(12):e647-56 24194350 - Neurochem Res. 2013 Dec;38(12):2668-77 11898581 - Curr Neurol Neurosci Rep. 2002 Jan;2(1):38-43 7619022 - Arch Neurol. 1995 Jul;52(7):670-5 9368550 - Stroke. 1997 Nov;28(11):2109-18 8784243 - J Cereb Blood Flow Metab. 1996 Sep;16(5):981-7 23691430 - Stroke Res Treat. 2013;2013:362961 22710066 - Neuroscience. 2012 Sep 18;220:302-12 26189021 - Eur J Pharmacol. 2015 Oct 5;764:404-12 24649933 - Eur J Neurosci. 2014 Jun;39(12):2107-18 15207256 - Neurobiol Dis. 2004 Jun;16(1):1-13 18927459 - Stroke. 2008 Dec;39(12):3372-7 19036971 - J Neurosci. 2008 Nov 26;28(48):12788-97 21277149 - J Vasc Surg. 2011 Apr;53(4):1044-51 22435369 - N Engl J Med. 2012 Mar 22;366(12 ):1099-107 10512933 - Stroke. 1999 Oct;30(10):2230-7 27289487 - Lancet Neurol. 2016 Aug;15(9):925-33 15459442 - Stroke. 2004 Nov;35(11 Suppl 1):2726-30 22244977 - Neuroscience. 2012 Mar 15;205:39-48 9664164 - Curr Opin Hematol. 1998 May;5(3):221-5 17596135 - J Thromb Haemost. 2007 Aug;5(8):1732-9 27217508 - Stroke. 2016 Jun;47(6):1584-92 24172582 - Stroke. 2013 Dec;44(12):3490-7 22574982 - Curr Pharm Des. 2012;18(25):3677-84 25899606 - Basic Clin Pharmacol Toxicol. 2015 Nov;117(5):335-9 27758945 - Stroke. 2016 Nov;47(11):2874-2876 26055229 - Mol Neurobiol. 2015 Oct;52(2):979-84 21852620 - Stroke. 2011 Sep;42(9):2645-50 17392177 - Am J Pathol. 2007 Apr;170(4):1389-97 21934531 - J Hypertens. 2011 Nov;29(11):2210-9 21727900 - Leukemia. 2011 Nov;25(11):1674-86 16846501 - BMC Neurosci. 2006 Jul 17;7:56 25367883 - Mol Neurobiol. 2015 Dec;52(3):1572-9 15579073 - Curr Pharm Des. 2004;10(30):3813-33 25425079 - J Cereb Blood Flow Metab. 2015 Feb;35(2):338-46 16275125 - Atheroscler Suppl. 2005 Dec 15;6(4):33-40 10328970 - Exp Eye Res. 1999 May;68(5):565-72 21151895 - PLoS One. 2010 Dec 06;5(12):e15178 |
| References_xml | – start-page: 2109 volume-title: Intracerebral hemorrhage after intravenous tPA therapy for ischemic stroke year: 1997 ident: ref4 – ident: ref15 doi: 10.1186/1471-2202-7-56 – ident: ref44 doi: 10.1007/s12975-012-0209-2 – ident: ref43 doi: 10.1161/STROKEAHA.111.618850 – ident: ref36 doi: 10.1111/ejn.12551 – ident: ref18 doi: 10.1161/STROKEAHA.111.618215 – ident: ref29 doi: 10.1097/00004647-199609000-00023 – ident: ref35 doi: 10.2174/1381612043382710 – ident: ref31 doi: 10.1016/j.ejphar.2015.07.035 – ident: ref38 doi: 10.1038/jcbfm.2014.208 – ident: ref23 doi: 10.1016/j.neuroscience.2011.12.042 – ident: ref25 doi: 10.3171/jns.1992.76.4.0571 – ident: ref20 doi: 10.1016/j.atherosclerosissup.2005.09.003 – ident: ref40 doi: 10.1177/0148607106030002108 – ident: ref52 doi: 10.1056/NEJMoa1411587 – ident: ref32 doi: 10.1016/j.jvs.2010.10.117 – ident: ref7 doi: 10.1007/s12035-014-8952-x – ident: ref5 doi: 10.2174/187152707783220901 – ident: ref24 doi: 10.1161/01.STR.32.1.240 – ident: ref47 doi: 10.1016/j.neulet.2015.06.050 – ident: ref39 doi: 10.1111/j.1538-7836.2010.03897.x – ident: ref51 doi: 10.1016/j.nicl.2014.02.003 – ident: ref28 doi: 10.1111/j.1538-7836.2007.02628.x – ident: ref14 doi: 10.1371/journal.pone.0015178 – ident: ref16 doi: 10.1161/STROKEAHA.108.514026 – ident: ref46 doi: 10.1038/jcbfm.2010.33 – ident: ref33 doi: 10.1186/2045-8118-11-18 – ident: ref57 doi: 10.1001/archneur.1995.00540310040014 – ident: ref26 doi: 10.1097/HJH.0b013e32834bbb30 – ident: ref42 doi: 10.1007/s12035-015-9243-x – ident: ref1 doi: 10.1161/01.STR.30.10.2230 – ident: ref54 doi: 10.1177/1941874415576204 – ident: ref41 doi: 10.1111/bcpt.12413 – start-page: 561 volume-title: Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro year: 1981 ident: ref45 – ident: ref56 doi: 10.1161/STROKEAHA.116.014672 – ident: ref3 doi: 10.1161/01.cir.0000441139.02102.80 – ident: ref8 doi: 10.1007/s12035-014-8952-x – ident: ref6 doi: 10.1161/01.STR.0000064841.47697.22 – ident: ref48 doi: 10.1038/jcbfm.2009.279 – ident: ref58 doi: 10.1056/NEJMoa1109842 – ident: ref13 doi: 10.1016/j.neuroscience.2012.06.015 – ident: ref53 doi: 10.1161/STROKEAHA.116.012619 – ident: ref10 doi: 10.1007/s11910-002-0051-0 – ident: ref49 doi: 10.1038/leu.2011.167 – ident: ref17 doi: 10.1161/STROKEAHA.110.582601 – ident: ref60 doi: 10.1161/STROKEAHA.109.564872 – ident: ref11 doi: 10.1038/jcbfm.2013.163 – ident: ref55 doi: 10.1016/S1474-4422(16)30076-X – ident: ref12 doi: 10.1016/j.nbd.2003.12.016 – ident: ref19 doi: 10.1155/2013/362961 – ident: ref27 doi: 10.1007/s11064-013-1185-y – ident: ref21 doi: 10.2353/ajpath.2007.060693 – ident: ref61 doi: 10.2174/138161212802002779 – ident: ref30 doi: 10.1161/STROKEAHA.113.002411 – ident: ref2 doi: 10.1056/NEJMoa0804656 – ident: ref22 doi: 10.1006/exer.1998.0637 – start-page: 371 year: 2015 ident: ref50 – ident: ref37 doi: 10.1097/00062752-199805000-00013 – ident: ref9 doi: 10.1038/jcbfm.2013.203 – ident: ref59 doi: 10.1007/s12975-015-0444-4 – ident: ref34 doi: 10.1523/JNEUROSCI.3485-08.2008 – reference: 25367883 - Mol Neurobiol. 2015 Dec;52(3):1572-9 – reference: 6795744 - Thromb Haemost. 1981 Aug 28;46(2):561-5 – reference: 25899606 - Basic Clin Pharmacol Toxicol. 2015 Nov;117(5):335-9 – reference: 23658596 - Transl Stroke Res. 2013 Jun;4(3):279-85 – reference: 15579073 - Curr Pharm Des. 2004;10(30):3813-33 – reference: 12677087 - Stroke. 2003 Apr;34(4):1056-83 – reference: 20705929 - Stroke. 2010 Oct;41(10):2283-7 – reference: 11898581 - Curr Neurol Neurosci Rep. 2002 Jan;2(1):38-43 – reference: 21737808 - Stroke. 2011 Sep;42(9):2633-5 – reference: 9368550 - Stroke. 1997 Nov;28(11):2109-18 – reference: 20456746 - J Thromb Haemost. 2010 Jul;8(7):1567-74 – reference: 16846501 - BMC Neurosci. 2006 Jul 17;7:56 – reference: 16275125 - Atheroscler Suppl. 2005 Dec 15;6(4):33-40 – reference: 17392177 - Am J Pathol. 2007 Apr;170(4):1389-97 – reference: 19036971 - J Neurosci. 2008 Nov 26;28(48):12788-97 – reference: 22435369 - N Engl J Med. 2012 Mar 22;366(12 ):1099-107 – reference: 21151895 - PLoS One. 2010 Dec 06;5(12):e15178 – reference: 24194350 - Neurochem Res. 2013 Dec;38(12):2668-77 – reference: 26739964 - Transl Stroke Res. 2016 Aug;7(4):284-93 – reference: 21852620 - Stroke. 2011 Sep;42(9):2645-50 – reference: 24281743 - J Cereb Blood Flow Metab. 2014 Feb;34(2):185-99 – reference: 11136943 - Stroke. 2001 Jan;32(1):240-8 – reference: 10512933 - Stroke. 1999 Oct;30(10):2230-7 – reference: 26189021 - Eur J Pharmacol. 2015 Oct 5;764:404-12 – reference: 25425079 - J Cereb Blood Flow Metab. 2015 Feb;35(2):338-46 – reference: 22244977 - Neuroscience. 2012 Mar 15;205:39-48 – reference: 24936414 - Neuroimage Clin. 2014 Mar 30;4:635-40 – reference: 27217508 - Stroke. 2016 Jun;47(6):1584-92 – reference: 20068577 - J Cereb Blood Flow Metab. 2010 Jun;30(6):1137-46 – reference: 18927459 - Stroke. 2008 Dec;39(12):3372-7 – reference: 19834012 - Stroke. 2009 Dec;40(12):e647-56 – reference: 22574982 - Curr Pharm Des. 2012;18(25):3677-84 – reference: 26149229 - Neurosci Lett. 2015 Aug 18;602:73-8 – reference: 24172582 - Stroke. 2013 Dec;44(12):3490-7 – reference: 20216551 - J Cereb Blood Flow Metab. 2010 May;30(5):900-3 – reference: 16517955 - JPEN J Parenter Enteral Nutr. 2006 Mar-Apr;30(2):108-14 – reference: 26288674 - Neurohospitalist. 2015 Jul;5(3):161-72 – reference: 10328970 - Exp Eye Res. 1999 May;68(5):565-72 – reference: 26055229 - Mol Neurobiol. 2015 Oct;52(2):979-84 – reference: 18815396 - N Engl J Med. 2008 Sep 25;359(13):1317-29 – reference: 23691430 - Stroke Res Treat. 2013;2013:362961 – reference: 22710066 - Neuroscience. 2012 Sep 18;220:302-12 – reference: 1545249 - J Neurosurg. 1992 Apr;76(4):571-7 – reference: 24352519 - Circulation. 2014 Jan 21;129(3):e28-e292 – reference: 21934531 - J Hypertens. 2011 Nov;29(11):2210-9 – reference: 25120903 - Fluids Barriers CNS. 2014 Aug 10;11:18 – reference: 24649933 - Eur J Neurosci. 2014 Jun;39(12):2107-18 – reference: 21727900 - Leukemia. 2011 Nov;25(11):1674-86 – reference: 17596135 - J Thromb Haemost. 2007 Aug;5(8):1732-9 – reference: 21277149 - J Vasc Surg. 2011 Apr;53(4):1044-51 – reference: 24045404 - J Cereb Blood Flow Metab. 2014 Jan;34(1):72-80 – reference: 18045160 - CNS Neurol Disord Drug Targets. 2007 Oct;6(5):321-5 – reference: 25517348 - N Engl J Med. 2015 Jan 1;372(1):11-20 – reference: 15459442 - Stroke. 2004 Nov;35(11 Suppl 1):2726-30 – reference: 9664164 - Curr Opin Hematol. 1998 May;5(3):221-5 – reference: 7619022 - Arch Neurol. 1995 Jul;52(7):670-5 – reference: 27758945 - Stroke. 2016 Nov;47(11):2874-2876 – reference: 8784243 - J Cereb Blood Flow Metab. 1996 Sep;16(5):981-7 – reference: 15207256 - Neurobiol Dis. 2004 Jun;16(1):1-13 – reference: 27289487 - Lancet Neurol. 2016 Aug;15(9):925-33 |
| SSID | ssj0000851882 ssib007599070 ssib016587330 |
| Score | 2.382481 |
| SecondaryResourceType | review_article |
| Snippet | To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5... |
| SourceID | nrf doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 50 |
| SubjectTerms | blood-brain barrier hemorrhage Review tissue plasminogen activator vasculature 신경과학 |
| Title | Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28178410 https://www.proquest.com/docview/1866691794 https://pubmed.ncbi.nlm.nih.gov/PMC5307939 https://doaj.org/article/f5b9a89b95834718b472665c8c842847 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002194038 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 대한뇌졸중학회지, 2017, 19(1), 17, pp.50-60 |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2287-6405 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000851882 issn: 2287-6391 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwED7BhBAviPFrATYZhMRTWBwnsc3bmDaxByoeOtE3K_Zs1rVLUNqB-O-5c9KqnUC88FSptSXXd7nvu_j8HcBbXXGrJN1uLy_ytODSURx0qUPolFVACFF1bDYhRyM1megvG62-qCaslwfuN-4wlFbXSltdKkGB1BYSMaV0yqmCQitFX2Q9G8nUVV99xVXsFJVjSpAiDPNesRHZsTi8akmom1fvM4LzLUSKwv2IM00X_sQ5b5dObmDR6SN4OJBIdtQvfhfu-OYx3P88HJM_AbfSnPULtmzZSXzRzcaXXXtt2_kvnMXo6gf7igl5-5Mhb2VnmOVSnTzDqe3Ms_GqAP0DO2rYeXPtl2zQEJ2zEULeUzg_PRkff0qHbgqpw30rUy5r5UokFMFyW9SZF7yuLXdKCO5tVvhMW-VCraTXpShymwcXMln5kiMr4U48g52mbfwesAunC86rEJCNFUIEBH1bWYHcRgSNjCqBdLWjxg1S49TxYm4w5SALGLSAIQuYaIEE3q3Hf-9FNv468iMZaD2KxLHjF-gyZnAZ8y-XSeANmtfM3DTOp89vrZl1BlOIM0N3ytGjEni9sr7BJ46OUerGtzcLQxKBlaZAlsDz3hvW68kVp4PcLAG55SdbC97-pZleRlXvUpBWoX7xP_7hS3iQE_2Ir4pewc6yu_H7cM_9WE4X3QHclRN1EB-Y35JTE3g |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Strategies+to+Extend+Thrombolytic+Time+Window+for+Ischemic+Stroke+Treatment%3A+An+Unmet+Clinical+Need&rft.jtitle=Journal+of+stroke&rft.au=Pe%C3%B1a%2C+Ike+Dela&rft.au=Borlongan%2C+Cesar&rft.au=Shen%2C+Guofang&rft.au=Davis%2C+Willie&rft.date=2017-01-01&rft.issn=2287-6391&rft.volume=19&rft.issue=1&rft.spage=50&rft_id=info:doi/10.5853%2Fjos.2016.01515&rft_id=info%3Apmid%2F28178410&rft.externalDocID=28178410 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2287-6391&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2287-6391&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2287-6391&client=summon |